TABLE 4. Reported cases of notifiable diseases and rates per 100,000, by age, excluding U.S. territories - - United States, 2017 column labels in same order that data fields appears in each record below: Disease <1 yr, No. <1 yr, Rate 1-4 yrs, No. 1-4 yrs, Rate 5-14 yrs, No. 5-14 yrs, Rate 15-24 yrs, No. 15-24 yrs, Rate 25-39 yrs, No. 25-39 yrs, Rate 40-64 yrs, No. 40-64 yrs, Rate >=65 yrs, No. >=65 yrs, Rate Age not stated, No. Total, No. tab delimited data: Anthrax — — — — — — — — — — — — — — — — Arboviral diseases, Chikungunya virus disease — — — — 6 0.01 13 0.03 37 0.06 83 0.08 17 0.03 — 156 Arboviral diseases, Eastern equine encephalitis virus disease, Neuroinvasive — — — — — — 1 0.00 1 0.00 3 0.00 — — — 5 Arboviral diseases, Eastern equine encephalitis virus disease, Non-neuroinvasive — — — — — — — — — — — — — — — — Arboviral diseases, Jamestown Canyon virus disease, Neuroinvasive — — — — 3 0.01 4 0.01 6 0.01 26 0.02 19 0.04 — 58 Arboviral diseases, Jamestown Canyon virus disease, Non-neuroinvasive — — — — — — 1 0.00 3 0.00 7 0.01 6 0.01 — 17 Arboviral diseases, La Crosse virus disease, Neuroinvasive 3 0.08 7 0.04 41 0.10 5 0.01 3 0.00 1 0.00 3 0.01 — 63 Arboviral diseases, La Crosse virus disease, Non-neuroinvasive — — — — — — — — — — — — — — — — Arboviral diseases, Powassan virus disease, Neuroinvasive — — — — 4 0.01 1 0.00 1 0.00 12 0.01 15 0.03 — 33 Arboviral diseases, Powassan virus disease, Non-neuroinvasive — — — — — — — — — — — — 1 0.00 — 1 Arboviral diseases, St. Louis encephalitis virus disease, Neuroinvasive — — — — — — — — 1 0.00 4 0.00 1 0.00 — 6 Arboviral diseases, St. Louis encephalitis virus disease, Non-neuroinvasive — — — — — — — — — — 4 0.00 1 0.00 — 5 Arboviral diseases, West Nile virus disease, Neuroinvasive — — 2 0.01 15 0.04 35 0.08 127 0.19 621 0.60 625 1.23 — 1,425 Arboviral diseases, West Nile virus disease, Non-neuroinvasive — — 4 0.03 7 0.02 41 0.09 145 0.22 325 0.31 150 0.29 — 672 Arboviral diseases, Western equine encephalitis virus disease, Neuroinvasive — — — — — — — — — — — — — — — — Arboviral diseases, Western equine encephalitis virus disease, Non-neuroinvasive — — — — — — — — — — — — — — — — Babesiosis, Total 1 0.03 4 0.03 54 0.17 48 0.14 149 0.29 969 1.20 1,132 2.88 11 2,368 Babesiosis, Confirmed 1 0.03 2 0.02 35 0.11 36 0.11 124 0.24 793 0.98 995 2.53 8 1,994 Babesiosis, Probable — — 2 0.02 19 0.06 12 0.04 25 0.05 176 0.22 137 0.35 3 374 Botulism, Total 131 3.33 4 0.03 2 0.00 3 0.01 11 0.02 17 0.02 6 0.01 3 177 Botulism, Foodborne 1 0.03 — — 1 0.00 3 0.01 4 0.01 6 0.01 4 0.01 — 19 Botulism, Infant * 130 3.30 4 — — — — — — — — — — — 3 137 Botulism, Other (wound & unspecified) — — — — 1 0.00 — — 7 0.01 11 0.01 2 0.00 — 21 Brucellosis — — 2 0.01 7 0.02 15 0.03 36 0.05 48 0.05 32 0.06 — 140 Campylobacteriosis 1,936 49.15 6,328 39.55 5,270 12.83 7,461 17.25 12,027 18.07 21,445 20.62 12,931 25.43 139 67,537 Chancroid — — — — — — 3 0.01 3 0.00 1 0.00 — — — 7 Chlamydia trachomatis infection 420 10.66 93 0.58 10,893 26.51 1,069,111 2,471.92 540,510 811.89 83,917 80.68 2,178 4.28 1,447 1,708,569 Cholera — — — — — — 1 0.00 3 0.00 4 0.00 2 0.00 — 10 Coccidioidomycosis † 7 0.44 70 1.07 520 3.10 1,200 6.81 2,734 10.15 6,101 14.64 3,725 18.39 7 14,364 Cryptosporidiosis, Total 130 3.30 1,246 7.79 1,306 3.18 1,822 4.21 2,870 4.31 2,680 2.58 1,319 2.59 41 11,414 Cryptosporidiosis, Confirmed 97 2.46 978 6.11 955 2.32 1,343 3.11 2,081 3.13 1,834 1.76 728 1.43 27 8,043 Cryptosporidiosis, Probable 33 0.84 268 1.68 351 0.85 479 1.11 789 1.19 846 0.81 591 1.16 14 3,371 Cyclosporiasis — — 9 0.06 17 0.05 90 0.23 278 0.46 546 0.58 222 0.48 32 1,194 Dengue virus infections, Dengue § 1 0.03 2 0.01 33 0.08 57 0.13 139 0.21 169 0.16 36 0.07 — 437 Dengue virus infections, Dengue-like illness § — — — — 1 0.00 2 0.00 1 0.00 4 0.00 — — — 8 Dengue virus infections, Severe dengue § — — — — — — 1 0.00 4 0.01 4 0.00 — — — 9 Diphtheria — — — — — — — — — — — — — — — — Ehrlichiosis and Anaplasmosis, Anaplasma phagocytophilum infection — — 24 0.16 147 0.37 156 0.37 479 0.75 2,455 2.44 2,483 5.05 18 5,762 Ehrlichiosis and Anaplasmosis, Ehrlichia chaffeensis infection — — 11 0.07 44 0.11 99 0.24 195 0.30 720 0.72 569 1.16 4 1,642 Ehrlichiosis and Anaplasmosis, Ehrlichia ewingii infection — — — — — — 1 0.00 2 0.00 25 0.03 17 0.04 — 45 Ehrlichiosis and Anaplasmosis, Undetermined ehrlichiosis/anaplasmosis — — 3 0.02 8 0.02 25 0.06 40 0.06 114 0.11 76 0.16 3 269 Giardiasis 113 3.73 1,388 11.26 1,557 4.92 1,792 5.32 3,378 6.49 5,040 6.15 1,883 4.61 42 15,193 Gonorrhea 90 2.28 113 0.71 2,835 6.90 248,470 574.49 237,275 356.40 64,403 61.92 2,063 4.06 359 555,608 Haemophilus influenzae, invasive disease, All ages, all serotypes 363 9.21 262 1.64 116 0.28 137 0.32 354 0.53 1,456 1.40 2,852 5.61 8 5,548 Haemophilus influenzae, invasive disease, Age <5 years, Serotype b ¶ 17 0.43 16 0.10 — — — — — — — — — — — 33 Haemophilus influenzae, invasive disease, Age <5 years, Non-b serotype ¶ 92 2.34 97 0.61 — — — — — — — — — — — 189 Haemophilus influenzae, invasive disease, Age <5 years, Nontypeable ¶ 140 3.55 60 0.38 — — — — — — — — — — — 200 Haemophilus influenzae, invasive disease, Age <5 years, Unknown serotype ¶ 114 2.89 89 0.56 — — — — — — — — — — — 203 Hansen's disease — — — — 1 0.00 4 0.01 16 0.03 32 0.03 23 0.05 18 94 Hantavirus infection, non-hantavirus pulmonary syndrome — — — — — — 1 0.00 1 0.00 — — — — — 2 Hantavirus pulmonary syndrome — — — — — — 1 0.00 10 0.02 15 0.01 7 0.01 — 33 Hemolytic uremic syndrome post-diarrheal 6 0.16 156 1.00 90 0.22 39 0.09 7 0.01 20 0.02 18 0.04 2 338 Hepatitis, A, acute ** 1 0.03 19 0.12 44 0.11 255 0.59 1,358 2.04 1,345 1.29 338 0.66 5 3,365 Hepatitis, B, acute ** — — 2 0.01 — — 99 0.23 1,183 1.79 1,881 1.82 242 0.48 2 3,409 Hepatitis, B, perinatal infection **,†† 22 0.56 8 0.20 — — — — — — — — — — 1 31 Hepatitis, C, acute ** 13 0.35 21 0.14 2 0.01 669 1.63 2,234 3.52 1,149 1.16 105 0.22 32 4,225 Hepatitis, C, acute, Confirmed ** 11 0.29 18 0.12 1 0.00 514 1.25 1,681 2.65 874 0.88 84 0.17 30 3,213 Hepatitis, C, acute, Probable ** 2 0.05 3 0.02 1 0.00 155 0.38 553 0.87 275 0.28 21 0.04 2 1,012 Human immunodeficiency virus diagnoses 32 0.81 15 0.09 49 0.12 7,040 16.28 15,561 23.37 10,459 10.06 782 1.54 — 33,938 Influenza-associated pediatric mortality §§ 16 0.41 31 0.19 64 0.16 15 0.12 — — — — — — — 126 Invasive pneumococcal disease, All ages ¶¶ 435 14.87 733 6.17 500 1.64 325 1.01 1,491 3.05 8,007 10.30 8,062 20.91 227 19,780 Invasive pneumococcal disease, All ages, Confirmed ¶¶ 432 14.76 724 6.09 490 1.61 322 1.00 1,481 3.03 7,942 10.22 8,002 20.75 227 19,620 Invasive pneumococcal disease, All ages, Probable ¶¶ 3 0.10 9 0.08 10 0.03 3 0.01 10 0.02 65 0.08 60 0.16 — 160 Invasive pneumococcal disease, Age <5 years ¶¶,¶ 454 14.39 780 6.09 — — — — — — — — — — — 1,234 Invasive pneumococcal disease, Age <5 years, Confirmed ¶¶,¶ 450 14.27 770 6.01 — — — — — — — — — — — 1,220 Invasive pneumococcal disease, Age <5 years, Probable ¶¶,¶ 4 0.13 10 0.08 — — — — — — — — — — — 14 Legionellosis 1 0.03 4 0.03 2 0.00 55 0.13 529 0.79 3,453 3.32 3,412 6.71 2 7,458 Leptospirosis — — — — 2 0.01 8 0.02 19 0.04 32 0.04 11 0.03 — 72 Listeriosis 37 0.94 3 0.02 8 0.02 23 0.05 86 0.13 221 0.21 504 0.99 5 887 Lyme disease, Total 24 0.61 1,580 9.92 6,489 15.86 3,801 8.82 5,570 8.40 15,005 14.49 9,396 18.57 878 42,743 Lyme disease, Confirmed 21 0.54 1,309 8.22 4,816 11.77 2,500 5.80 3,724 5.62 10,463 10.10 6,034 11.92 646 29,513 Lyme disease, Probable 3 0.08 271 1.70 1,673 4.09 1,301 3.02 1,846 2.79 4,542 4.39 3,362 6.64 232 13,230 Malaria 6 0.15 61 0.38 214 0.52 309 0.71 556 0.84 772 0.74 137 0.27 1 2,056 Measles, Total 11 0.28 58 0.36 20 0.05 11 0.03 8 0.01 11 0.01 1 0.00 — 120 Measles, Indigenous 7 0.18 55 0.34 18 0.04 7 0.02 5 0.01 6 0.01 1 0.00 — 99 Measles, Imported 4 0.10 3 0.02 2 0.00 4 0.01 3 0.00 5 0.00 — — — 21 Meningococcal disease, All serogroups 26 0.66 20 0.13 23 0.06 75 0.17 53 0.08 81 0.08 75 0.15 — 353 Meningococcal disease, Serogroups ACWY 4 0.10 3 0.02 3 0.01 7 0.02 20 0.03 38 0.04 32 0.06 — 107 Meningococcal disease, Serogroup B 12 0.30 6 0.04 7 0.02 37 0.09 6 0.01 11 0.01 11 0.02 — 90 Meningococcal disease, Other serogroups — — 2 0.01 2 0.00 8 0.02 7 0.01 1 0.00 5 0.01 — 25 Meningococcal disease, Unknown serogroup 10 0.25 9 0.06 11 0.03 23 0.05 20 0.03 31 0.03 27 0.05 — 131 Mumps 13 0.33 184 1.15 1,083 2.64 2,471 5.71 1,424 2.14 831 0.80 94 0.18 9 6,109 Novel Influenza A virus infections 1 0.03 8 0.05 9 0.02 1 0.00 — — 1 0.00 — — 46 66 Pertussis 2,237 56.79 2,779 17.37 6,015 14.64 4,204 9.72 1,035 1.55 1,924 1.85 739 1.45 42 18,975 Plague — — — — — — — — — — 3 0.00 2 0.00 — 5 Poliomyelitis, paralytic — — — — — — — — — — — — — — — — Poliovirus infection, nonparalytic — — — — — — — — — — — — — — — — Psittacosis — — — — 1 0.00 — — 1 0.00 2 0.00 1 0.00 — 5 Q fever, Total — — — — 3 0.01 4 0.01 25 0.04 103 0.10 58 0.11 — 193 Q fever, Acute — — — — 3 0.01 3 0.01 21 0.03 83 0.08 43 0.08 — 153 Q fever, Chronic — — — — — — 1 0.00 4 0.01 20 0.02 15 0.03 — 40 Rabies, Human — — — — — — — — — — 1 0.00 1 0.00 — 2 Rubella — — 1 0.01 — — 2 0.00 1 0.00 2 0.00 1 0.00 — 7 Rubella, congenital syndrome * 5 0.13 — — — — — — — — — — — — — 5 Salmonellosis 5,278 133.98 7,138 44.61 5,418 13.19 5,018 11.60 7,723 11.60 14,219 13.67 9,223 18.13 268 54,285 Severe acute respiratory syndrome-associated coronavirus disease — — — — — — — — — — — — — — — — Shiga toxin-producing Escherichia coli *** 309 7.84 1,860 11.63 1,383 3.37 1,654 3.82 1,268 1.90 1,209 1.16 921 1.81 68 8,672 Shigellosis 226 5.74 3,036 18.98 2,876 7.00 1,339 3.10 3,048 4.58 3,204 3.08 1,078 2.12 105 14,912 Smallpox — — — — — — — — — — — — — — — — Spotted fever rickettsiosis, Total 2 0.05 68 0.43 286 0.70 488 1.14 1,209 1.83 2,787 2.70 1,402 2.77 6 6,248 Spotted fever rickettsiosis, Confirmed — — 7 0.04 7 0.02 6 0.01 37 0.06 84 0.08 35 0.07 — 176 Spotted fever rickettsiosis, Probable 2 0.05 61 0.38 279 0.68 482 1.12 1,172 1.77 2,703 2.62 1,367 2.71 6 6,072 Streptococcal toxic shock syndrome 4 0.16 4 0.04 17 0.07 11 0.04 58 0.14 156 0.23 122 0.37 — 372 Syphilis, Total, all stages 924 23.46 4 0.03 55 0.13 19,761 45.69 49,521 74.38 29,296 28.17 1,972 3.88 34 101,567 Syphilis, Congenital * 918 23.30 — — — — — — — — — — — — — 918 Syphilis, Primary and secondary 3 0.08 2 0.01 21 0.05 7,001 16.19 15,288 22.96 7,967 7.66 349 0.69 13 30,644 Tetanus — — — — 3 0.01 — — 5 0.01 6 0.01 7 0.01 12 33 Toxic shock syndrome (other than Streptococcal) — — 2 0.02 15 0.05 5 0.02 1 0.00 3 0.00 4 0.01 — 30 Trichinellosis — — — — — — 1 0.00 6 0.01 5 0.01 3 0.01 — 15 Tuberculosis 53 1.35 175 1.09 201 0.49 847 1.96 2,162 3.25 3,354 3.22 2,305 4.53 8 9,105 Tularemia 1 0.03 10 0.06 39 0.09 11 0.03 35 0.05 100 0.10 43 0.08 — 239 Typhoid fever 2 0.05 49 0.31 94 0.23 57 0.13 123 0.18 77 0.07 16 0.03 1 419 Vancomycin-intermediate Staphylococcus aureus — — 2 0.02 1 0.00 6 0.02 15 0.03 39 0.05 46 0.12 — 109 Vancomycin-resistant Staphylococcus aureus — — — — — — — — — — 1 0.00 2 0.00 — 3 Varicella morbidity 724 22.34 1,881 14.31 3,039 9.02 867 2.45 836 1.53 633 0.75 110 0.27 685 8,775 Varicella mortality U U U U U U U U U U U U U U U U Vibriosis, Total 18 0.46 44 0.28 141 0.35 124 0.29 360 0.55 830 0.81 560 1.12 8 2,085 Vibriosis, Confirmed 4 0.10 20 0.13 123 0.30 90 0.21 258 0.39 617 0.60 379 0.76 6 1,497 Vibriosis, Probable 14 0.36 24 0.15 18 0.04 34 0.08 102 0.16 213 0.21 181 0.36 2 588 Viral hemorrhagic fevers, Crimean-Congo hemorrhagic fever virus — — — — — — — — — — — — — — — — Viral hemorrhagic fevers, Ebola virus — — — — — — — — — — — — — — — — Viral hemorrhagic fevers, Guanarito virus — — — — — — — — — — — — — — — — Viral hemorrhagic fevers, Junin virus — — — — — — — — — — — — — — — — Viral hemorrhagic fevers, Lassa virus — — — — — — — — — — — — — — — — Viral hemorrhagic fevers, Lujo virus — — — — — — — — — — — — — — — — Viral hemorrhagic fevers, Machupo virus — — — — — — — — — — — — — — — — Viral hemorrhagic fevers, Marburg virus — — — — — — — — — — — — — — — — Viral hemorrhagic fevers, Sabia virus — — — — — — — — — — — — — — — — Yellow fever — — — — — — — — — — — — — — — — Zika virus, Zika virus disease, congenital *,††† 22 0.56 — — — — — — — — — — — — — 22 Zika virus, Zika virus disease, non-congenital — — 4 0.03 15 0.04 84 0.19 172 0.26 183 0.18 39 0.08 — 497 Zika virus, Zika virus infection, congenital *,††† 17 0.43 — — — — — — — — — — — — — 17 Zika virus, Zika virus infection, non-congenital — — — — — — 193 0.45 411 0.62 33 0.03 4 0.01 — 641 —: No reported cases - The reporting jurisdiction did not submit any cases to CDC. U: Unavailable - The data are unavailable. * The rate is calculated using population less than 1 year of age. † Reportable in <25 states. § Total number of reported laboratory-positive dengue cases, including all confirmed cases [by anti-dengue virus (DENV) molecular diagnostic methods or seroconversion of anti-DENV IgM] and all probable cases (by a single, positive anti-DENV IgM). ¶ The rate is calculated using population less than 5 years of age. ** Chronic hepatitis B and C data are not included in NNDSS tables but reported case counts are included in the annual Summary of Viral Hepatitis, published online by CDC's Division of Viral Hepatitis, available at https://www.cdc.gov/hepatitis/statistics/2016surveillance/index.htm. †† The rate is calculated using population less than 2 years of age. §§ The rate is calculated using population less than 18 years of age. ¶¶ Includes drug resistant and susceptible cases of Invasive Pneumococcal Disease. This condition was previously named Streptococcus pneumoniae invasive disease and cases were reported to CDC using different event codes to specify whether the cases were drug resistant or in a defined age group, such as <5 years. *** Includes Escherichia coli O157:H7 and Shiga toxin-positive Escherichia coli (including O157, non-O157, and not serogrouped). ††† Data reported to ArboNET using the national surveillance case definition for congenital Zika virus disease or infection (CSTE Position Statement 16-ID-01). Additional data reported to the US Zika Pregnancy Registry for outcomes of pregnancies with laboratory evidence of possible Zika virus infection are available at https://www.cdc.gov/pregnancy/zika/data/pregnancy-outcomes.html. Cases reported to the US Zika Pregnancy Registry might not meet the national surveillance case definition for congenital Zika virus disease or infection. Notes: These are annual cases of selected infectious national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published. Cases are reported by state health departments to CDC weekly. Because source datasets may be updated as additional information is received, statistics in publications based on that source data may differ from what is presented in these tables. The list of nationally notifiable infectious diseases and conditions for 2018 and their national surveillance case definitions are available by navigating to the https://ndc.services.cdc.gov/, Surveillance Case Definitions | CDC web page, selecting "2017" for the notifiable condition list year, checking "infectious" conditions, and clicking "Get Notifiable List by Year". This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved in 2016 by CSTE for national surveillance, that were implemented in January 2017, including updated surveillance case definitions for salmonellosis, shigellosis, vibrioisis, perinatal hepatitis B virus infection, invasive pneumococcal disease, Lyme disease, and tularemia reported through August 7, 2018. Publication criteria for the finalized 2017 data are available at https://wonder.cdc.gov/nndss/documents/2017_NNDSS_Publication_Criteria.pdf, https://wonder.cdc.gov/nndss/documents/2017_NNDSS_Publication_Criteria.pdf. See also https://ndc.services.cdc.gov/wp-content/uploads/Users_guide_WONDER_tables_cleared_final.pdf, Guide to Interpreting Provisional and Finalized NNDSS Data. Population estimates for incidence rates are July 1st, 2017 estimates obtained from the National Center for Health Statistics (NCHS) postcensal estimates of the resident population of the United States for April 1, 2010 - July 1, 2017, by year, county, single year of age (range: 0 to 85 years), bridged-race (white, black or African American, American Indian or Alaska Native, Asian, or Pacific Islander), Hispanic ethnicity (not Hispanic or Latino, Hispanic or Latino), and sex (Vintage 2017), prepared under a collaborative arrangement with the U.S. Census Bureau. Population estimates for states released June 27, 2018 are available at https://www.cdc.gov/nchs/nvss/bridged_race/data_documentation.htm, https://www.cdc.gov/nchs/nvss/bridged_race/data_documentation.htm. Population estimates for territories are the 2017 mid-year estimates from the U.S. Census Bureau International Data Base, accessed on October 2, 2018 at https://www.census.gov/data-tools/demo/idb/informationGateway.php, https://www.census.gov/data-tools/demo/idb/informationGateway.php. The choice of population denominators for incidence is based on the availability of population data at the time of publication preparation. Annual tables for 2016 and later years are available on https://wonder.cdc.gov/nndss/nndss_annual_tables_menu.asp, CDC WONDER. Annual summary reports from 1993-2015 are available as published in the https://www.cdc.gov/mmwr/mmwr_nd/index.html, MMWR. NNDSS annual tables since 1952 are available at https://stacks.cdc.gov/nndss, CDC Stacks (once in CDC Stacks select "Annual Reports" in the "Genre" box to the left). Suggested Citation: Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System, 2017 Annual Tables of Infectious Disease Data. Atlanta, GA. CDC Division of Health Informatics and Surveillance, 2018. Available at: https://www.cdc.gov/nndss/data-statistics/infectious-tables/index.html, https://www.cdc.gov/nndss/data-statistics/infectious-tables/index.html. https://www.cdc.gov/nndss/, National Notifiable Diseases Surveillance System Provided by https://wonder.cdc.gov, CDC WONDER